Regulation & Compliance

Digital Supply Networks Become Reality in Chemicals, Energy Industries

February 6, 2019

The chemicals and energy market is ripe for continued growth — even in uncertain times of geopolitical, environmental and regulatory compliance unrest.

How to Minimize Damage From Foodborne Outbreaks Before They Happen

February 6, 2019

Angela Fernandez, SCB Contributor

The increasing complexity and interconnected nature of today’s food supply chain calls for proactive risk mitigation — at every step in the supply chain.

How Hazmat Shipping Compliance Can Impact Your Business

February 6, 2019

Alicia Saenz, SCB Contributor

Shipping and handling hazardous materials can have serious operational, financial and environmental ramifications for shippers.

Importing and Exporting: The Most Important Thing to Remember

February 6, 2019

Beth Pride, SCB Contributor

Before last year, companies hadn’t put much thought into their products' harmonized tariff schedule (HTS).

Huawei's Worst-Case Survival Guide for U.S. Criminal Crackdown

February 4, 2019

Bloomberg

Huawei needs to be able to keep buying components from American suppliers, particularly semiconductors and optical gear, so that it can sell equipment to customers in Asia, Africa and beyond.

Improving the Lot of the Global Supply Chain Worker

February 4, 2019

Robert J. Bowman, SupplyChainBrain

Neither technology nor traditional compliance measures will prevent the mistreatment of factory workers in the global supply chain.

Pursuit of Value, Good Data Underlie Healthcare Supply-Chain Trends in 2019

January 31, 2019

Karen Conway, SCB Contributor

The continuing pursuit of value-based healthcare is at the crux of many of the trends that will impact the healthcare supply chain in 2019.

America’s Love for Cheap Drugs Has a Hidden Cost

An investigation into the generic-drug industry shows reason to doubt the data meant to prove safety and effectiveness

January 29, 2019

Bloomberg

Concerns about quality control and data integrity have focused on companies in India and China, where more and more ingredients used in medicine for the U.S. are being made. But those concerns aren’t limited to overseas factories, according to a year-long investigation into FDA’s regulation of the generic-drug industry.